Agricultural Opportunities
Executive Summary
Millennium's recent blockbuster deal with Monsanto isn't in healthcare--it's in agriculture. Now other drug-oriented biotechs are considering whether they too can leverage their discovery assets this way. Some firms believe their technologies are directly translatable; others say ag companies can't afford to pay for the methods. The big question: whether to do exclusive deals.You may also be interested in...
Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
Fledgling Pharma FerGene Makes Quick Debut With Gene Therapy Candidate
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.
Need a specific report? 1000+ reports available
Buy Reports